2002
Monoclonal antibodies to target epidermal growth factor receptor–positive tumors
Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor–positive tumors. Cancer 2002, 94: 1593-1611. PMID: 11920518, DOI: 10.1002/cncr.10372.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorAnti-EGFR monoclonal antibodiesMonoclonal antibodiesHuman tumorsEnglish-language literature searchEpidermal growth factor receptor (EGFR) positive tumorsMonoclonal antibody therapyReceptor-positive tumorsEGFR monoclonal antibodyDevelopment of malignancyGrowth of tumorsABX-EGFGrowth factor receptorIMC-C225Overall survivalAntibody therapyTraditional cytotoxicsCommon malignancyPoor prognosisClinical trialsEpithelial tumorsVivo effectsTumor managementUnmet needEMD 55900
2000
9:00—9:15 Antiangiogenic Treatment with Endostatin Results in Uncoupling of Blood Flow and Glucose Metabolism in Human Tumors
Mullani N, Herbst R, Abbruzzese J, Charnsangavej C, Kim E, Tran H, Barron B, Lamki L, Gould K. 9:00—9:15 Antiangiogenic Treatment with Endostatin Results in Uncoupling of Blood Flow and Glucose Metabolism in Human Tumors. Molecular Imaging And Biology 2000, 3: 151. PMID: 11150754, DOI: 10.1016/s1095-0397(00)00063-7.Peer-Reviewed Original ResearchStandard uptake valueTumor blood flowBlood flowGlucose metabolismImaged tumorsTumor-bearing sitesStart of therapyTumor metabolic activityRegional blood flowNovel antiangiogenic agentsDays of treatmentNon-invasive imagingAntiangiogenic treatmentAntiangiogenic agentsPatientsDose levelsUptake valueTumorsHuman tumorsPercentage changePhase IOxygen-15Flourine-18TreatmentDose